B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
暂无分享,去创建一个
D. Arnold | A. Bar-Or | E. Waubant | A. Langer-Gould | S. Hauser | T. Vollmer | R. Fox | J. Antel | M. Panzara | S. Agarwal | N. Sarkar | Craig H. Smith
[1] R. De Palma,et al. Rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.
[2] F. Breedveld,et al. Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response , 2007, Journal of clinical pharmacology.
[3] M. Duddy,et al. Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis , 2007, The Journal of Immunology.
[4] M. Trojano,et al. New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .
[5] P. Narayana,et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.
[6] M. Trojano,et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. , 2007, Annals of neurology.
[7] R. Reynolds,et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.
[8] M. Duddy,et al. B-cells in multiple sclerosis. , 2006, International MS journal.
[9] H. Link,et al. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.
[10] S. Hauser,et al. The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.
[11] Stanley B. Cohen,et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.
[12] M. Krumbholz,et al. B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation , 2006, Annals of neurology.
[13] J. Bennett,et al. The B cell response in multiple sclerosis , 2006, Neurological research.
[14] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[15] W. Robinson,et al. Lipid microarrays identify key mediators of autoimmune brain inflammation , 2006, Nature Medicine.
[16] R. Sobel,et al. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions , 2005, Journal of Neuroimmunology.
[17] D. Hafler,et al. Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein1 , 2005, The Journal of Immunology.
[18] A. Uccelli,et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[19] Å. Sidén. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS , 1979, Journal of Neurology.
[20] A. Bar-Or,et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions , 2003, Journal of Neuroimmunology.
[21] K. Digre. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. , 2002 .
[22] Freddy Ståhlberg,et al. Combined diffusion weighting and CSF suppression in functional MRI , 2002, NMR in biomedicine.
[23] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[24] E. E. Max,et al. All about B Cells , 2001 .
[25] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[26] D. Gilden,et al. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response , 2000, Neurology.
[27] N. Chiorazzi,et al. Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.
[28] S. Baranzini,et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. , 1999, Journal of immunology.
[29] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .
[30] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.
[31] S. Hauser,et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.
[32] D. Gilden,et al. Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.
[33] D. R. Anderson,et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. , 1997, Biochemical Society transactions.
[34] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[35] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[36] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[37] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[38] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.